title: Evaluation of six risk factors for the development of bacteremia in children with cancer and febrile neutropenia.
abstract: Febrile neutropenia is a well-known entity in children with cancer, being responsible for the high risk for infection that characterizes this population. For this reason, cancer patients are hospitalized so that they can receive prophylactic care. Risk factors have been used to classify patients at a high risk for developing bacteremia. The present study evaluates whether those risk factors (C-reactive protein, hypotension, leukemia as the cancer type, thrombocytopenia, recent chemotherapy, and acute malnutrition) apply to patients at the Unidad Nacional de Oncología Pediátrica. We evaluated 102 episodes in 88 patients, in whom risk factors and blood cultures were tested. We observed no statistical relationship between the six risk factors and bacteremia. There was also no relationship between bacteremia and the simultaneous presence of two, three, or more risk factors. A significant relationship of C-reactive protein and platelet count with other outcome factors was observed.
authors.affiliation: Unidad Nacional de Oncología Pediátrica, Guatemala City, Guatemala.
authors.forename: E J
authors.initials: EJ
authors.lastname: Asturias
authors.forename: J E
authors.initials: JE
authors.lastname: Corral
authors.forename: J
authors.initials: J
authors.lastname: Quezada
references.citation: Clin Infect Dis. 2002 Mar 15;34(6):730-51
references.pmid: 11850858
references.citation: Support Care Cancer. 2002 Jan;10(1):58-64
references.pmid: 11778605
references.citation: Cancer. 1996 Feb 15;77(4):791-8
references.pmid: 8616774
references.citation: Pediatr Infect Dis J. 1995 Feb;14(2):140-3
references.pmid: 7746697
references.citation: J Clin Oncol. 2001 Jul 15;19(14):3415-21
references.pmid: 11454890
references.citation: Med Dosw Mikrobiol. 2004;56(4):411-9
references.pmid: 15959998
references.citation: J Clin Oncol. 2000 Mar;18(5):1012-9
references.pmid: 10694551
references.citation: N Engl J Med. 1999 Sep 16;341(12):893-900
references.pmid: 10486422
references.citation: Pediatr Hematol Oncol. 1998 Sep-Oct;15(5):405-13
references.pmid: 9783306
references.citation: Int J Antimicrob Agents. 2005 Jun;25(6):469-73
references.pmid: 15890499
references.citation: Pediatr Crit Care Med. 2005 May;6(3 Suppl):S80-6
references.pmid: 15857564
references.citation: Clin Cornerstone. 2006;8 Suppl 5:S12-8
references.pmid: 17379159
references.citation: Pediatr Blood Cancer. 2007 Oct 15;49(5):678-81
references.pmid: 17066460
references.citation: Int J Antimicrob Agents. 2008 Nov;32 Suppl 1:S30-3
references.pmid: 18778919
references.citation: Pediatr Crit Care Med. 2005 May;6(3 Suppl):S87-91
references.pmid: 15857565
references.citation: Pediatr Hematol Oncol. 2008 Apr-May;25(3):195-204
references.pmid: 18432502
references.citation: Crit Care Clin. 2006 Jul;22(3):503-19, ix-x
references.pmid: 16893736
references.citation: Clin Infect Dis. 2002 Sep 15;35(6):678-83
references.pmid: 12203164